Jeries Kort

Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.

CancerNetwork® visited Mary’s Place by the Sea, a cancer treatment center in Neptune Township, New Jersey, to speak with Alison Ankiewicz, PT, DPT, to learn more about how oncology clinicians can best collaborate with pelvic floor physical therapists to elevate the quality of care for patients undergoing treatment for cancer. Specifically, Ankiewicz highlighted the indicators or symptoms that medical oncologists should search for that may indicate a need for specialized care.

The conclusion of active cancer treatment marks a significant milestone, yet it often initiates a new set of psycho-social challenges. While medical teams excel at addressing the cancer itself, clinical social worker Kelly Dyckman, MSW, LCSW, from the Navesink Wellness Center, highlights a critical gap in care: the information provided to patients regarding these post-treatment issues is often reactive, not proactive.